Literature DB >> 15105189

Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.

Michael J Eisses1, Kristy Seidel, Gabriel S Aldea, Wayne L Chandler.   

Abstract

UNLABELLED: Interventions such as heparin-coated circuits, epsilon-aminocaproic acid, and reduced shed blood reinfusion have shown mixed results when applied individually for limiting hemostatic activation during cardiopulmonary bypass (CPB). We compared coagulation and fibrinolytic activation during conventional CPB (control) (CTRL) using noncoated circuits, no antifibrinolytics, and open cardiotomy with a combined strategy (HAC) that used heparin-coated circuits, epsilon-aminocaproic acid, and closed cardiotomy. Blood samples were drawn before, during, and after CPB for primary coronary bypass grafting surgery from 9 CTRL patients and 10 HAC patients. Thrombin-antithrombin complex and fibrinopeptide A levels (markers of thrombin and fibrin generation) were reduced in the HAC versus CTRL group after 30 min of CPB (P < 0.05). Average tissue plasminogen activator (tPA) levels were significantly lower in the HAC group by 30 min on CPB (P < 0.05), resulting in preservation of plasminogen activator inhibitor (PAI)-1 during CPB (P < 0.05). D-Dimer, a measure of intravascular fibrin formation and removal, was reduced in the HAC group during and after CPB (P < 0.005). Overall, the combined strategy was associated with a reduction in CPB-induced increases in markers of thrombin generation, fibrin formation, tPA release, and fibrin degradation and better preservation of PAI-1. IMPLICATIONS: A combined approach during cardiopulmonary bypass (CPB) that uses heparin-coated circuits, epsilon-aminocaproic acid, and limited reinfusion of shed pericardial blood is associated with reduced activation of the coagulation and fibrinolytic systems that typically occurs during conventional CPB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105189     DOI: 10.1213/01.ane.0000108489.88613.2c

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements.

Authors:  Alice Wiefferink; Patrick W Weerwind; Waander van Heerde; Steven Teerenstra; Luc Noyez; Ben E de Pauw; René M H J Brouwer
Journal:  J Extra Corpor Technol       Date:  2007-06

2.  Plasmin generation and fibrinolysis in pediatric patients undergoing cardiopulmonary bypass surgery.

Authors:  Vera Ignjatovic; Aparajith Chandramouli; Jenny Than; Robyn Summerhayes; Fiona Newall; Steve Horton; Andrew Cochrane; Paul Monagle
Journal:  Pediatr Cardiol       Date:  2011-10-02       Impact factor: 1.655

3.  Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.

Authors:  J M Balaguer; C Yu; J G Byrne; S K Ball; M R Petracek; N J Brown; M Pretorius
Journal:  Clin Pharmacol Ther       Date:  2012-12-24       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.